Monthly Archives: April 2012

Clinical Trial Highlights Positive Oncoprex Results in Lung Cancer Patients

A clinical trial has demonstrated that Oncoprex® (TUSC2 nanoparticles) can be safely administered in advanced lung cancer patients to halt cancer or shrink primary and metastatic tumors in some patients.

Read More

Oncoprex Shows Synergistic Tumor Suppression in Combination with AKT Inhibitor MK2206

New data demonstrating the anti-cancer activities of Oncoprex® were presented at the 2012 Annual Meeting of the American Association for Cancer Research (AACR) in Chicago IL.

Read More